DropScreen, ViewAllergy39 Not Equally Effective for Detecting Allergens
By Elana Gotkine HealthDay Reporter
Medically reviewed by Drugs.com

MONDAY, July 14, 2025 -- DropScreen (DS) and ViewAllergy39 (VA) are not equally effective for detecting specific immunoglobulin (Ig) E involved in pollinosis, according to a study recently published online in the Journal of Immunoassay and Immunochemistry.
Tomohiro Ono, Ph.D., from Ono Otolaryngology Clinic in Kakogawa, Japan, and colleagues compared performance of the DS point-of-care test with that of VA, a laboratory test for identifying causative aeroallergens, in patients with pollinosis. Sera were obtained from 70 Japanese outpatients with pollinosis.
The researchers found that for the 17 allergens included in the study, the average positivity rates were 20.8 and 26.6 percent for DS and VA, respectively. For Japanese cypress, the DS positive rate was 10-fold lower than that of VA. For Japanese cedar, Moth, and Aspergillus fumigatus, clear discrepancies were seen in detection rates between VA and DS. Inhibition tests on discrepant sera confirmed that specific IgE toward these allergens could be accurately measured using VA.
"Our findings confirm that not all specific IgE tests are equally powerful in aiding clinicians in the identification of allergens associated with pollinosis," the authors write. "Further studies of the potential impact of testing performance differences on diagnostic workup and subsequent therapy selection are needed."
Several authors disclosed ties to Thermo Fisher Diagnostics, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-15 12:00
Read more

- Breast Cancer Risk in Younger Women May Be Influenced by Hormone Therapy
- Late-Life Mood Disorders May Indicate Predisposition to Dementia
- Marine Microplastic Levels Linked to Cardiometabolic Disease Prevalence
- FDA Sends Warning Letters to Companies Selling Illegal Opioid Compound
- AI Boosts Skin Cancer Diagnoses, Study Says
- Studies Address Muscle Loss Caused By GLP-1 Drugs, such as Ozempic and Zepbound
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions